Previous 10 | Next 10 |
Aptinyx Reports Completion of Enrolment in NYX-783 Trial Aptinyx ( APTX ) reported completion of enrollment in its NYX-783 trial. This phase 2 study aims to assess the safety and efficacy of NYX-783 in treating patients with post-traumatic stress disorder (PTSD). The company expects the ...
The FDA approves Ultragenyx Pharmaceutical's ( RARE +1.0% ) Crysvita (burosumab-twza) for the treatment of patients at least two years old with tumor-induced osteomalacia (TIO), a rare disorder characterized by weakened bones at high-risk of fracture. More news on: Ultragenyx Pharmac...
First Approved Therapy in the United States for Patients with TIO Who Cannot Undergo Surgical Removal of Tumors TIO is Second FDA-Approved Indication for Crysvita, Which is Also Approved for the Treatment of X-linked Hypophosphatemia (XLH) NOVATO, Calif. and TOKYO, J...
Investment Thesis The coming weeks could unveil two new FDA approvals for Ultragenyx Pharmaceutical Inc. ( RARE ), boosting its efforts to sustain the growth momentum. Expecting the Phase 3 trial starts as early as this year, two more candidates are undergoing mid-stage studies with their ...
Arcturus Therapeutics ' (NASDAQ: ARCT) stock saw deep losses on May 27, in part because of spillover from news about patients in Moderna 's (NASDAQ: MRNA) COVID-19 vaccine trial experiencing adverse reactions. Because both companies are working on COVID-19 vaccines, bad news ...
NOVATO, Calif. and SAN DIEGO, May 21, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical, Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases and Arcturus Therapeutics Holdings I...
All Patients in Cohort 3 Demonstrate Increased Time to Hypoglycemia and a Substantial Reduction in Cornstarch Use Introduction of Continuous Glucose Monitoring Reveals Early Transgene Expression and Enables More Rapid Reduction in Cornstarch Ultragenyx to Host ASGCT Recap Investor ...
All three patients in Cohort 3 now confirmed responders All three complete responders in the study remain clinically and metabolically stable after longer-term follow-up Ultragenyx to host ASGCT recap investor conference call Friday, May 15 at 8:30 a.m. Eastern Time NOVATO...
By Marshall Gordon and Nicholas Wu, PhD Healthcare, a Key Part of Solution to COVID-19 Healthcare has been the best-performing sector since the U.S. market peaked in February. This is reasonable because 1) the underlying demand for a large proportion of healthcare goods and services, par...
NOVATO, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Shalini Sharp, the company's Chief Financial Office...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...